Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Valneva SE ADR (VALN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Valneva SE's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7.55 -0.20    -2.58%
- Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 52,747
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 7.28 - 7.99
Valneva SE 7.55 -0.20 -2.58%

Valneva SE ADR Company Profile

 
Get an in-depth profile of Valneva SE ADR, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

719

Equity Type

ADR

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Contact Information

Address 6 rue Alain Bombard
Saint-Herblain, 44800
France
Phone 33 2 28 07 37 10
Fax 33 2 28 07 37 11

Top Executives

Name Age Since Title
Thomas Lingelbach 61 2013 President, CEO & Director
Anne-Marie Graffin 63 2013 Chairman
Alexander Von Gabain 74 2013 Member of Scientific Advisory Board
Mailys Ferrere 62 2022 Director
Norman W. Baylor - 2019 Member of Scientific Advisory Board
Thomas Decker - 2022 Member of Scientific Advisory Board
Kathrin U. Jansen - 2023 Director
Michael Pfleiderer - 2022 Member of Scientific Advisory Board
George R. Siber 79 2019 Member of Scientific Advisory Board
James Edward Connolly 58 2022 Director
Ralf Leo Clemens 70 2016 Chair of Scientific Advisory Board
James R. Sulat 74 2013 Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VALN Comments

Write your thoughts about Valneva SE ADR
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Dominique NIFFLE
Dominique NIFFLE Sep 27, 2022 1:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
6,90 December, 31
Despoina Alterlife
Despoina Alterlife Sep 17, 2022 2:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
120$ on December .
Jan Jensen
MadeForStreets Sep 17, 2022 2:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why do you think that, because Pfizer has thrown 24 millions in the company, Goldman said they wanted it down to 16$ but it is currently at 11$ lower than Goldman said, what makes you think that it will go from 11$ to 120$ in a month..???? 🤔✌
Despoina Alterlife
Despoina Alterlife Sep 17, 2022 2:02PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
secret
Dominique NIFFLE
Dominique NIFFLE Jul 18, 2022 1:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
8 in december ...
Dominique NIFFLE
Dominique NIFFLE May 19, 2022 12:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
tomorrow , some will cry for having invested more thann 20
Stephen Ford
Investor1985 May 19, 2022 12:39PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why?
Dominique NIFFLE
Dominique NIFFLE Mar 09, 2022 2:07PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the cend for me , thanks and good lucks
Gabor Kisari
Gabor Kisari Jan 20, 2022 9:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What happened since yesterday?
scott mccain
scott mccain Jan 20, 2022 9:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Booster is now in phase 3. Final phase. Expecting France purchase agreement this week also.
scott mccain
scott mccain Jan 17, 2022 6:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Headed to 100.00 this week
Nono London
Nono London Jan 17, 2022 6:51PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
haha if only, been a big source of desapointment this stock, so was NVAX...
GB BG
GB BG Dec 09, 2021 1:44PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Halted ?
Oliver DiTwister
Oliver DiTwister Dec 06, 2021 8:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Strong buy now!
raz inski
raz inski Nov 12, 2021 3:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Everybody should dump Pfizer for this great
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email